TEL AVIV, ISRAEL, Nov. 24, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”) is a clinical-stage specialist company focused on developing treatments for disease. It’s a pharmaceutical company. A clinical trial using SCI-210, a unique treatment for the symptoms of autism spectrum disorder (ASD), a rare disease of the central nervous system, has begun at Soroka Medical Center in Israel.
SciSparc’s new SCI-210 therapy is not only a CBD-based drug; It is also a unique combination of cannabidiol (CBD) and his SciSparc proprietary palmitoylethanolamide, which is intended to alleviate symptoms of ASD.
How does it work?
The 20-week trial will enroll 60 participants between the ages of 5 and 18 and will provide a scientific study of how SCI-210 compares to standard CBD treatment in the management of ASD symptoms. Measure to. The study is structured as a randomized, double-blind, placebo-controlled trial, the gold standard in clinical research.
Oz Adler, CEO of SciSparc, said: “Our pioneering therapy reduces the side effects commonly seen when taking cannabis-based treatments such as CBD, while also helping to treat autism. The goal is to reduce and alleviate symptoms. “At the National Center for Autism Research, we are exploring new areas of ASD treatment. We are driven by the goal of improving the quality of life for families.”
The spectrum of ASD is as diverse as the individuals affected, and it presents difficulties with social interaction and communication. SciSparc’s bold initiative aims to provide a brighter, more connected future for people on the autism spectrum.
About SciSparc Ltd. (NASDAQ: SPRC):
SciSparc Ltd. is a clinical-stage specialty pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc is focused on creating and enhancing its portfolio of technologies and assets based on cannabinoid medicines. With this focus, we are currently working on the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette’s syndrome, for the treatment of Alzheimer’s disease and agitation. SCI-160 is for pain treatment. and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business is focused on selling hemp seed oil-based products. Amazon.com market.
Forward-looking statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, when discussing the goals and objectives of the SCI-210 clinical trial and the company’s optimism that SCI-210 could be a pioneer in the treatment of ASD, SciSparc commented on future prospects. using description. Because such statements address future events and are based on SciSparc’s current expectations, they are subject to a variety of risks and uncertainties, and SciSparc’s actual results, performance and achievements may differ from those in this press release. may differ materially from that described or implied by the description. The forward-looking statements contained in or implied by this press release are discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023. may be subject to other risks and uncertainties, including risks and uncertainties related to In subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. To do. These statements speak only as of the date on which they are made.
Investor contact information:
[email protected]
Phone number: +972-3-6167055
